CD8A and type 1 diabetes mellitus: The mechanism of action is not fully understood, but data from two randomized clinical studies of teplizumab in new- and recent-onset T1D patients revealed that clinical responders showed a significant reduction in circulating CD4+ effector memory T cells and an increase in the frequency and absolute number of CD8+ central memory T cells [142].